Puration Reports First Revenue from Patented Cannabis Extraction and Progress Toward $3 Million Annual Revenue Target

Thursday, May 18, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

DALLAS, May 18, 2017 /PRNewswire/ --

Puration, Inc. (USOTC: PURA) has published an online on demand earnings presentation

reviewing the Company's first quarter 2017 financial report.  In addition to a review of the most recent financial results, which highlights the Company's first reported revenue from its patented cannabis extraction business, the report also includes
details about the pending transaction with American Cannabis Innovations Conglomerated with specific mention that PURA stock will remain listed on the OTC Markets and will not be subject to a reverse split.  The report also includes details about the Company's plans with NCM Biotech to pursue the development of cannabis pharmaceuticals.  Furthermore, the report includes the latest updates on the Companies three cannabis infused beverage contracts and its target $3 million in annual revenue.

REVIEW THE ENTIRE PURA EARNINGS REPORT

To learn more about Puration: purationinc.com

To learn more about NCM Biotech: ncmbiotech.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Puration Contact: Brian Shibley, CEO [email protected] +1-214-937-9097

SOURCE Puration, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook